A Clinical Study of Iparomlimab and Tuvonralimab Combined With SOX Following Heterogeneous Radiotherapy as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Gastric or Gastroesophageal Junction Adenocarcinoma
PHASE4
This study is a domestic, multicenter, single-arm clinical trial designed t...
Iparomlimab and Tuvonralimab (QL1706) Combined With Chemotherapy for Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer
PHASE2
The goal of this Phase II clinical trial is to evaluate the efficacy and sa...
Status
Recruiting
Location
Beijing Friendship Hospital, Capital Medical University
A Multicenter Randomized Controlled Phase II Trial of Iparomlimab and Tuvonralimab (QL1706) Combined With SOX Chemotherapy Versus Chemotherapy Alone in the Treatment of Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
PHASE2
To explore the efficacy of Iparomlimab and Tuvonralimab (QL1706) in combina...